Accelerated TMS for MDD

Prior treatment

• History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes
• Any disorder which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening
• Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation

Other illness

• Current diagnosis of substance use disorder (Abuse or Dependence, as defined by DSM-V-TR), with the exception of nicotine dependence
• History of non-response to TMS or ECT
• History of any implanted device or psychosurgery for depression
• Have any medical or psychological condition, that in the opinion of the referring psychiatrist or investigator, would prevent the participant from completing the study, put the participant at unacceptable risk or could interfere with study assessments or integrity of the data

Other

• Participants satisfy any one or more of the contraindications for TMS per current treatment guidelines as determined by the PI
• Total MADRS score of \< 20 or PHQ-score \<10 at the screen or baseline visits
• Displaying symptoms of substance withdrawal
• Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results
• PI opinion: Considered at significant risk for suicide during the course of the study

• Male or female
• 15 years and older
• Able to provide informed consent or/and assent
• Diagnosed with major depressive disorder (MDD) and currently experiencing a major depressive episode (MDE)
• Adult participants failed to respond to at least one prior anti-depressant medication; for adolescent participants, TMS therapy is used as an adjunct treatment as stated in the FDA cleared indications, but failure to respond adequately to prior anti-depressant medication is not required
• Participant prescribed TMS Therapy to treat MDD by his or her physician independent of potential participation in this clinical study
• On a stable antidepressant treatment regimen (whether medication, therapy, other methods or no treatment at all) for at least the past 4 weeks and agrees to remain on the same treatment regimen throughout study enrollment
• Willing to comply with all the study procedures, complete required assessments and visits, and be available for the duration of the study